Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
World game at war: why some European nations have threatened a World Cup boycott 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
 Patients for FLT3 Mutations - EconoTimes)
SAN DIEGO, May 08, 2018 -- Invivoscribe Technologies, Inc. announced today that they have submitted to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) product registrations based on the ongoing Phase III CL-0301 ADMIRAL study evaluating gilteritinib for the treatment of FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia (AML) in adult patients.
Invivoscribe Technologies Inc., in collaboration with Astellas Pharma Inc., has developed a companion diagnostic to aid in identifying these FLT3mut+ AML patients. In Japan, Invivoscribe submitted a pre-market approval application (Shonin) with the PMDA for the LeukoStrat® CDx FLT3 Mutation Assay and in the United States, Invivoscribe submitted a Panel Track Supplement to update the FDA-approved LeukoStrat CDx FLT3 Mutation Assay’s Intended Use, specific for gilteritinib, should it be approved.
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with AML. Invivoscribe was the first company to receive FDA approval for an AML companion diagnostic, with the approval of the LeukoStrat CDx FLT3 Mutation Assay in April of 2017.
“These submissions in Japan and the US represent a significant step in our ongoing efforts to harmonize molecular diagnostic testing for what is one of the most important driver mutations in AML in support of precision medicine,” said Jeffrey Miller, CSO & CEO of Invivoscribe.
According to the American Cancer Society, each year around 20,000 new cases of AML are diagnosed in the US alone, with one-third of these being FLT3mut+.
Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics.
For additional information please visit www.invivoscribe.com.
CONTACT:
Kevin Dobyns 858-224-6600
